(Q35543168)

8 August 2017

0 references

1 reference

title

Use of tamoxifen in the treatment of malignant melanoma (English)

1 reference

8 August 2017

1 reference

1 reference

14 March 2024

author name string

Tony Reiman

2

1 reference

8 August 2017

Marko B. Lens

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14508820

14 March 2024

Amna F. Husain

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14508820

14 March 2024

language of work or name

English

0 references

publication date

1 October 2003

1 reference

full work available at URL

8 August 2017

https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/cncr.11644

file format

Portable Document Format

online access status

open access

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14508820

https://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1002%2Fcncr.11644

14 March 2024

1 reference

https://onlinelibrary.wiley.com/doi/full/10.1002/cncr.11644

14 March 2024

1 reference

14 March 2024

1 reference

8 August 2017

98

1 reference

8 August 2017

1355-1361

1 reference

8 August 2017

7

1 reference

Metastatic melanoma: chemotherapy to biochemotherapy

8 August 2017

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11644

7 January 2021

Oestrogen receptors in human malignant melanoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11644

7 January 2021

Estrogen receptor in malignant melanoma.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11644

7 January 2021

Absence of estrogen receptor in human melanoma as evaluated by a monoclonal antiestrogen receptor antibody

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11644

7 January 2021

The evidence for tamoxifen and chemotherapy as treatment for metastatic melanoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11644

7 January 2021

Treatment of metastatic malignant melanoma with dacarbazine plus tamoxifen

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11644

7 January 2021

Randomized, double-blind, placebo-controlled trial comparing the response rates of carmustine, dacarbazine, and cisplatin with and without tamoxifen in patients with metastatic melanoma. National Cancer Institute of Canada Clinical Trials Group.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11644

7 January 2021

A phase III randomized trial of dacarbazine and carboplatin with and without tamoxifen in the treatment of patients with metastatic melanoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11644

7 January 2021

Phase III trial of dacarbazine versus dacarbazine with interferon alpha-2b versus dacarbazine with tamoxifen versus dacarbazine with interferon alpha-2b and tamoxifen in patients with metastatic malignant melanoma: an Eastern Cooperative Oncology Gr

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11644

7 January 2021

Phase III clinical trial of the combination of cisplatin, dacarbazine, and carmustine with or without tamoxifen in patients with advanced malignant melanoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11644

7 January 2021

Improving the quality of reports of meta-analyses of randomised controlled trials: the QUOROM statement. Quality of Reporting of Meta-analyses

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11644

7 January 2021

The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomised trials

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11644

7 January 2021

Systematic reviews in health care: Assessing the quality of controlled clinical trials

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11644

7 January 2021

The effect of tamoxifen and cisplatin on the disease-free and overall survival of patients with high risk malignant melanoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11644

7 January 2021

A phase II study of high dose tamoxifen and weekly cisplatin in patients with metastatic melanoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11644

7 January 2021

Tamoxifen in Malignant Melanoma

7

1 reference

14 March 2024

Identifiers

DOI

10.1002/CNCR.11644

1 reference

8 August 2017

1 reference